← Back to headlines
Revolution Medicines Stock Surges Following Positive Pancreatic Cancer Drug Trial Data
Revolution Medicines announced that its highly anticipated drug for pancreatic cancer, daraxonrasib, has succeeded in a Phase 3 clinical trial, leading to a surge in the company's stock. This represents a potential breakthrough in treating the aggressive disease.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
